文献速递冠心病外科瓣膜外科

心脏手术中红细胞输注触发阈值的随机临床试验

A Randomized Clinical Trial of Red Blood Cell Transfusion Triggers in Cardiac Surgery.
PubMed 文献 · Ann Thorac Surg · 2017-08-16

该随机试验将722例冠状动脉旁路移植或瓣膜手术成人分配至血细胞比容24%或28%输注阈值,因无效边界在第二次中期分析时终止。复合结局无显著差异(OR 0.86,95%CI 0.29-2.54,P=0.71),但24%组输血更少(54% vs 75%,P<0.001),支持积极血液保护。

要点

  • 24%与28%血细胞比容阈值相比,复合发病和死亡无显著差异。
  • 24%阈值组红细胞输注率更低(54% vs 75%,P<0.001)。
  • 结果支持心脏手术中采用更积极的血液保护策略。

核心结论

  • 24%血细胞比容触发阈值与28%相比不增加不良结局,且红细胞使用更少,支持积极血液保护。

研究设计与样本

  • 随机对照试验,2007年3月至2014年8月两中心纳入722例冠状动脉旁路移植或瓣膜手术成人,24%组363例,28%组354例。
  • 主要终点为术后并发症和死亡的复合结局,采用平均相对效应广义估计方程模型评估。

主要发现

  • 复合结局无显著治疗效应(低 vs 高组平均相对效应OR 0.86,95%CI 0.29-2.54,P=0.71)。
  • 低组红细胞输注率54%,高组75%(P<0.001)。
  • 输血地点:手术室低组112例(31%)、高组208例(59%);ICU低组105例(31%)、高组115例(34%);病房低组41例(12%)、高组42例(13%)。
  • 输血前中位血细胞比容:低组22%(Q1=21%,Q3=23%),高组24%(Q1=22%,Q3=25%)。

临床怎么用

  • 心脏手术后可考虑采用24%血细胞比容作为限制性输血触发阈值以减少红细胞输注。

局限性

  • 研究因无效边界在第二次中期分析时提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Class I evidence supporting a threshold for transfusion in the cardiac surgical setting is scarce. We randomly allocated patients to a transfusion hematocrit trigger of 24% versus 28% to compare morbidity, mortality, and resource use. METHODS: From March 2007 to August 2014, two centers randomly assigned 722 adults undergoing coronary artery bypass graft surgery or valve procedures to a 24% hematocrit trigger (n = 363, low group) or 28% trigger (n = 354, high group). One unit of red blood cells was transfused if the hematocrit fell below the designated threshold. The primary endpoint was a composite of postoperative morbidities and mortality. Treatment effect was primarily assessed using an average relative effect generalized estimating equation model. RESULTS: At the second planned interim analysis, the a priori futility boundary was crossed, and the study was stopped. There was no detected treatment effect on the composite outcome (average relative effect odds ratio, low versus high, 0.86, 95% confidence interval: 0.29 to 2.54, p = 0.71). However, the low group received fewer red blood cell transfusions than the high group (54% versus 75%, p < 0.001), mostly administered in the operating room (low group, 112 [31%]; high group, 208 [59%]), followed by intensive care unit (low, 105 [31%]; high, 115 [34%]) and floor (low, 41 [12%]; high, 42 [13%]). The low group was exposed to lower hematocrits: median before transfusion, 22% (Q1 = 21%, Q3 = 23%) versus 24% (Q1 = 22%, Q3 = 25%). CONCLUSIONS: Negative exposures differed between treatment groups, with lower hematocrit in the 24% trigger group and more red blood cells used in the 28% group, but adverse outcomes did not differ. Because red blood cell use was less with a 24% trigger without adverse effects, our randomized trial results support aggressive blood conservation efforts in cardiac surgery.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Koch CG, Sessler DI, Mascha EJ, et al. A Randomized Clinical Trial of Red Blood Cell Transfusion Triggers in Cardiac Surgery. Ann Thorac Surg. 2017. PMID: 28821336. doi:10.1016/j.athoracsur.2017.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。